| Organizer | Conference Name | Month | Start Date | End Date | Days | Location |
| Pharmapack | Pacific Symposium on Biocomputing 2008 | January | 1/4/2008 | 1/8/2008 | 5 | Hawaii, USA |
| GSA | Genetic Analysis: Model Organisms to Human Biology 2 | January | 1/5/2008 | TBA | TBA | San Diego |
| GRC | Autophagy In Stress, Development and Disease | January | 1/6/2008 | TBA | TBA | Ventura Beach Marriott |
| CHI | Pep Talk | January | 1/7/2008 | 1/11/2008 | 5 | Coronado, CA |
| Biochemical Society | Mechanics & Control of Cytokinesis | January | 1/9/2008 | 1/12/2008 | 4 | Edinburgh, UK |
| WBR | Natural Products Conference 2008 | January | 1/10/2008 | 1/13/2008 | 4 | Bolans Village, Antigua and Barbuda |
| GTCbio | Aging & Anti-Aging | January | 1/10/2008 | 1/11/2008 | 2 | San Francisco, CA |
| Kenes International | Molecular Basis for Biological Membrane Organization | January | 1/12/2008 | TBA | TBA | Big Sky, Montana |
| GRC | Biomolecular Interactions & Methods | January | 1/13/2008 | TBA | TBA | Four Points Sheraton |
| GRC | Composites | January | 1/13/2008 | TBA | TBA | Crowne Plaza |
| CHI | High Content Analysis | January | 1/14/2008 | 1/17/2008 | 4 | San Francisco, CA |
| GTCbio | Oncology Biomarkers | January | 1/14/2008 | 1/15/2008 | 2 | San Francisco, CA |
| ACR | Radiation Therapy Oncology Group | January | 1/17/2008 | 1/20/2008 | 4 | San Diego, CA |
| Terrapinn Ltd. | 2nd Annual Medical Science Liaison Skill Set Training | January | 1/17/2008 | TBA | TBA | Philadelphia, PA |
| Zing | Drug Discovery Conference | January | 1/17/2008 | TBA | TBA | Bolans Village, Antigua and Barbuda |
| Biochemical Society | RNK UK 2008 | January | 1/18/2008 | 1/20/2008 | 3 | Windermere, UK |
| SORIS | BIOS 2008 | January | 1/19/2008 | 1/24/2008 | 6 | San Jose, CA |
| Saudi Society of Nephrology | SBE's 1st International Conference on Stem Cell Engineering | January | 1/20/2008 | 1/23/2008 | 4 | Coronado, CA |
| IGBF | The 12th Annual Drug Delivery Partnerships | January | 1/21/2008 | TBA | TBA | San Diego, CA |
| Messe Dusseldorf Asia | Predictive Human Toxicity & ADME/Tox Studies | January | 1/22/2008 | 1/25/2008 | 4 | Zurich, Switzerland |
| ACI | 2nd Imaging in Clinical Trials | January | 1/23/2008 | TBA | TBA | London, UK |
| IIR | 6th Annual Partnering with Central Labs, ECG and Imaging Core Labs | January | 1/23/2008 | TBA | TBA | Lake Buena Vista, FL |
| The Center for Business Intelligence | 5th Annual Specialty Pharmaceuticals, Biotech Therapies & Injectables | January | 1/24/2008 | TBA | TBA | Las Vegas, NV |
| The Center for Business Intelligence | 7th Annual Pharmaceutical Contact Centers | January | 1/24/2008 | TBA | TBA | TBD |
| ASCO | 2008 Gastrointestinal Cancers Symposium | January | 1/25/2008 | 1/27/2008 | 3 | Orlando, FL |
| SIR | Nuclear Medicine: 2008 PET & PET/CT | January | 1/27/2008 | 1/31/2008 | 5 | St. Kitts |
| BIO | Asia Partnering Conference 2008 | January | 1/28/2008 | 1/29/2008 | 2 | Tokyo, Japan |
| BIO | BIO-Asia | January | 1/28/2008 | 1/29/2008 | 2 | Tokyo, Japan |
| Biostec | International Joint Conference on Biomedical Engineering Systems and Technologies | January | 1/28/2008 | 1/31/2008 | 4 | Portugal |
| Euroscicon | Molecular Farming - plant biologicals | January | 1/28/2008 | 1/28/2008 | 1 | Welwyn Garden City, UK |
| Keystone Symposia | Translational Regulatory Mechanisms | January | 1/28/2008 | 2/2/2008 | 6 | Idaho, USA |
| PDA | Phacilitate Vaccine Forum Washington 2008 | January | 1/28/2008 | TBA | TBA | Washington DC |
| Phacilitate | Phacilitate Cell & Gene Therapy Forum 2008 | January | 1/28/2008 | TBA | TBA | Washington DC |
| The Center for Business Intelligence | 5th Annal Pharmaceutical Marketing Compliance Congress | January | 1/28/2008 | TBA | TBA | Washington, DC |
| GTCbio | Cytokines & Inflammation (5th Annual) | January | 1/28/2008 | 1/29/2008 | 2 | Orlando, Florida |
| CMP | ICSE USA | January | 1/29/2008 | 2/1/2008 | 4 | New Orleans, US |
| CMP | InformEx USA 2008 | January | 1/29/2008 | 2/1/2008 | 4 | New Orleans, LA |
| ACCME | 27th Annual Advanced Nephrology: Nephrology for the Consultant | January | 1/31/2008 | 2/2/2008 | 3 | San Diego, CA |
5 comments:
GTCbio's New Applications in Aging Research - http://gtcbio.com/userAgenda.aspx?id=113
was a major success. All the big names in aging research including Michael West, Leonard Guarente, Michael Rose and others were there.
Also a new company called Genescient was first featured at the meeting. Elixir, Sirtris and many other companies pale when compared to Genescient in terms of market potential...
I highly recommend this conference to everyone.
Another great meeting I attended was Oncology Biomarkers in San Francisco.
Very high level speakers, excellent attendance.
The meeting inspired me to start www.OncologyBiomarkers.com blog and to start working on a Biomarker Research market report.
Biogerontology Research Foundation receives charitable status from the Charity Commission
On Wednesday, May 14 Biogerontology Research Foundation (BGRF) has met the requirements of the Charity Commission for England and Wales and received a charitable status with the registration number 1124054.
Source: Biogerontology Research Foundation
Jun 11, 2008 08:22:53 Click to see PDF Version of this Press Release
FOR IMMEDIATE RELEASE
PRLog (Press Release) – Jun 11, 2008 – Reading, UK - On Wednesday, May 14 Biogerontology Research Foundation (BGRF) has met the requirements of the Charity Commission for England and Wales and received a charitable status with the registration number 1124054.
The mission of the BGRF is to support the application of our knowledge of the mechanisms of ageing to the relief of disability, suffering and disease in old age. The formal aims of the charity are to relieve sickness and preserve, protect and advance all or any aspects of the health of elderly persons and to advance the education of the public in the field of biogerontology
”The decision to grant the BGRF registration as a UK charity represents an important milestone in the effort to defeat the diseases of aging. It will provide us with a platform to direct resources towards drastically underfunded scientific research projects that target the causes of age-related disease, rather than just the symptoms. We are looking forward to engaging with the wider community for support in the pursuit of this important mission”, said Damian Crowe, Managing Trustee of the BGRF.
The BGRF will actively pursue and encourage projects identified by its scientific team as key to these goals. The science of the projects will be screened by a Scientific Advisory Board consisting of world-class researchers in biogerontology and related fields, in consultation with external experts as appropriate. Although these projects may be long term in nature, they will be designed to generate interim results and products that create academic and commercial interest, thereby bringing further resources into play and accelerating progress. As a key component of this strategy, The BGRF will seek appropriate Intellectual Property protection to encourage industry to apply the results of our projects quickly. Our long-term goal is to provide medical practitioners with the tools they need to enable effective and lasting remedies for the illnesses and disabilities of old age.
"The BGRF will fill an critical gap in the funding spectrum between basic research and its application to alleviate disease in old age. Our establishment as a registered charity is an important step in realising our research and its application to treating the casuses of those diseases", said William Bains, PhD, Trustee of the BGRF.
Donations to the BGRF are welcome. For more information on how to donate to the BGRF or provide qualified services on a volunteer basis, please contact Alex Zhavoronkov, PhD at alex.zhavoronkov@bg-rf.org.uk .
Details on the Charities Commission for England and Wales registration are available at charity-commission.gov.uk/registeredcharities/showcharity.asp?remchar=&chyno=dav1124054 .
About the Biogerontology Research Foundation:
The Biogerontology Research Foundation seeks to fill a gap within the research community, whereby the current scientific understanding of the ageing process is not yet being sufficiently exploited to produce effective medical interventions. The BGRF will fund research which, building on the body of knowledge about how ageing happens, will develop biotechnological interventions to remediate the molecular and cellular deficits which accumulate with age and which underlie the ill-health of old age. Addressing ageing damage at this most fundamental level will provide an important opportunity to produce the effective, lasting treatments for the diseases and disabilities of ageing, which are required to improve quality of life in the elderly. The BGRF seeks to use the entire scope of modern biotechnology to attack the changes that take place in the course of aging, and to address not just the symptoms of age-related diseases but also the mechanisms of those diseases.
About the Charity Commission for England and Wales
The Charity Commission for England and Wales is established by law as the regulator and registrar of charities in England and Wales. The aim of the Charity Commission is to provide the best possible regulation of these charities in order to increase charities’ efficiency and effectiveness and public confidence and trust in them.
The Charity Commission for England and Wales publication The Charity Commission and Regulation describes in more detail Commission’s values and operation as a regulator.
Contact:
Biogerontology Research Foundation
Kings Lodge
194 Kings Rd.
Reading, Berkshire
RG1 4NH, UK
www.bg-rf.org.uk
Alex Zhavoronkov, PhD
+44 20 8144 7774
alex.zhavoronkov@bg-fr.org.uk
At the Aging Research conference I also learned about an interesting concept of using isotope-stabilized compounds to combat ROS-associated damage. You can read about it at www.agingcell.com
That is an amazing article. Thanks for sharing it with us. nyt digits
Post a Comment